Loading...
Please wait, while we are loading the content...
Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
| Content Provider | Semantic Scholar |
|---|---|
| Author | Răducan, Anca Rugină, Sorin |
| Copyright Year | 2014 |
| Abstract | Background Hepatitis C virus infection is the main cause of chronic liver disease, and patients are at risk of developing liver cirrhosis and hepatocellular carcinoma. The treatment in CHC is the combination of pegylated interferon 2a (peg-IFN) and ribavirin (RBV), the standard therapy with 24 to 48 weeks regimen. Cutaneous adverse effects are common, with a higher incidence in combination therapy than in IFN alone, and when serious, discontinuation of therapy is mandatory. |
| Starting Page | P23 |
| Ending Page | P23 |
| Page Count | 1 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/1471-2334-14-S7-P23 |
| PubMed reference number | 4239681 |
| Volume Number | 14 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Fibrosis Hepatitis A Hepatitis C Virus Infection Hepatitis C, Chronic Incidence matrix Liver carcinoma Liver diseases Patients Ribavirin Virus Diseases chronic liver disease peginterferon alfa-2b |
| Content Type | Text |
| Resource Type | Article |